Search clinical trials for: Empagliflozin medium

Total 11240 results

Dong-A ST Co., Ltd.

Completed

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Type2 Diabetes

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Diabetes Mellitus, Type 1

Austria, Germany
Centre Hospitalier Universitaire Vaudois
University College, London; Great Ormond Street Hospital for Children NHS Foundation...

Not yet recruiting

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

Heart Failure

Switzerland, United Kingdom
Clinical Research Centre, Malaysia
University of Malaya; Ministry of Health, Malaysia

Recruiting

The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD) (EpiCAD)

Coronary Artery Disease

Malaysia
Assiut University

Not yet recruiting

SGLT2 Inhibitors and Perioperative Period

Perioperative Complication
National Taiwan University Hospital

Recruiting

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

Ventilator Lung | Heart Failure Acute

Taiwan
Sohag University

Not yet recruiting

The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

Fatty Liver, Nonalcoholic
October 6 University
University of Florida; Beni-Suef University; National Heart Institute, Egypt

Recruiting

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

Heart Failure | Genetic Polymorphisms

United States
Centro Universitario de Ciencias de la Salud, Mexico

Active, not recruiting

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication

Mexico
Beijing Anzhen Hospital

Recruiting

The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

Coronary Artery Disease | Diabete Mellitus

China
Kiyuk Chang
Seoul St. Mary's Hospital; Pusan National University Hospital; Korea University... and other collaborators

Recruiting

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients With Acute Myocardial Infarction, a Prospective, Multi-center Registry Study (RECORD-AMI)

Myocardial Infarction | Diabetes Mellitus, Type 2

Korea, Republic of
Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt
Boehringer Ingelheim
Eli Lilly and Company

Completed

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, France, Israel, Mexico, South Africa
University of Turin, Italy

Unknown

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors (GliRACo1)

Diabetes Mellitus, Type 2 | Body Weight Changes | Arterial Hypertension

Italy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan
Ain Shams University

Not yet recruiting

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Lupus Nephritis

Egypt
Centro Universitario de Ciencias de la Salud, Mexico

Unknown

Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Mexico
Medical University of Warsaw
Medical University of Graz; Medical University of Vienna; Poznan University of... and other collaborators

Recruiting

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY)

Acute Decompensated Heart Failure

Poland
University of Pisa

Unknown

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections. (UTI-flog)

Type 2 Diabetes | Urinary Tract Infections

Italy
Tel Aviv University

Unknown

Cardiovascular Effects of Empagliflozine (EMP)

Type 2 Diabetes
Assiut University

Not yet recruiting

Treatment of Patients With Diabetic Kidney Disease

Diabetic Kidney Disease
Center for Outcomes Research and Clinical Epidemiology...
Italian Society of Diabetology

Not yet recruiting

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial (GOLDEN-AGE)

Diabetes Mellitus, Type 2
Brigham and Women's Hospital

Unknown

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Diabetes Mellitus, Type 2

United States
Peking Union Medical College Hospital

Unknown

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
LG Chem

Unknown

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Type 2 Diabetes Mellitus

Korea, Republic of
University Medical Centre Ljubljana

Unknown

The Effects of Empagliflozin on Arterial Wall Characteristics

Diabetes Complications | Diabetes Mellitus, Type 1 | Vascular Stiffness | Hypoglycemic Agents

Slovenia
Boehringer Ingelheim
Eli Lilly and Company

Completed

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Diabetes Mellitus, Type 2

United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain, Ukraine
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Brazil, Canada, El Salvador, France, Korea, Republic of, New Zealand, Norway, Spain, Taiwan
Tanta University

Active, not recruiting

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

Diabetic Neuropathy Peripheral

Egypt
Imperial College London
Royal Brompton & Harefield NHS Foundation Trust

Not yet recruiting

Therapy to Maintain Remission in Dilated Cardiomyopathy (TRED-HF2)

Heart Diseases | Heart Failure | Cardiomyopathies | Cardiomyopathy, Dilated
Bio-innova Co., Ltd

Not yet recruiting

Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

Healthy Subjects
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Healthy

Germany
Boehringer Ingelheim

Completed

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Healthy

Canada
Collegium Medicum w Bydgoszczy

Recruiting

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment (DEMETER)

Metabolic Syndrome

Poland
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Healthy

Germany
The University of Hong Kong
Research Grant Council

Recruiting

Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B

Cirrhosis | NAFLD | Chronic Hepatitis b | Fibrosis, Liver | Empagliflozin | SGLT2 Inhibitors

Hong Kong
The University of Hong Kong
Food and Health Bureau, Hong Kong

Completed

Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

Non-alcoholic Fatty Liver Disease

Hong Kong
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.

Type 2 Diabetes

China
Boehringer Ingelheim

Completed

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Hypertension | Diabetes Mellitus, Type 2

United States
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Doris...

Recruiting

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Type2 Diabetes | Heart Failure With Preserved Ejection Fraction

United States
Chong Kun Dang Pharmaceutical

Unknown

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Diabetes Mellitus, Type II

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
Anita Saraf
The Pittsburgh Foundation

Not yet recruiting

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease (EmpaCHD)

Heart Failure | Adult Congenital Heart Disease

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Healthy

China
University of Pennsylvania

Recruiting

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

Heart Failure With Preserved Ejection Fraction

United States
Yale University
Boehringer Ingelheim

Recruiting

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease (EMPA-PD)

End Stage Renal Disease on Dialysis

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

Type 1 Diabetes | Type 2 Diabetes

United States
Eli Lilly and Company

Completed

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (AWARD-10)

Type 2 Diabetes Mellitus

Czechia, Hungary, United States, Mexico, Germany, Austria, Israel, Puerto Rico, Spain

Search clinical trials for: Empagliflozin medium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations